Introduction & background
Company Presentation
Ongoing Projects
Marketed Products
CRO Services
About us
Products & Services
R&D Structure
Commercial Targets
  Contact us

Rivastigmine Patch for LATAM markets

Amarin Technologies S.A. has licensed its Rivastigmine Patch to Asofarma S.A., for Brazil and Argentina markets.

Registration is expected to be accomplished during 2013.

Rivastigmine patch is a drug-in-adhesive transdermal system which inhibits the cholinesterase activity and is indicated for the treatment of Alzheimer disease and Parkinson's disease dementia.



Helm AG Aquires Shares in Amarin Technologies S.A.

Hamburg, December 10th, 2010[+]


New Building for Amarin Technologies S.A.



Relocation and new logo

The Board of Directors of Amarin Technologies SA announces a new stage in the Company strategies and targets.
Amarin has acquired a building in Buenos Aires city where the Company will increase and [+]


Fentanyl TDS New Markets

Amarin Technologies S.A. is proud to announce that Fentanyl TDS is being exported to Taiwan (as Fentanyl HPQ, for Bio-Pro), since March 2009, and France (as Fentanyl Biogaran, for Biogaran), since [+]


New Fentanyl TDS Approvals & Brand Names

Fentanyl TDS received approval from the United [+]


Dolforin®, a new brand for Fentanyl TDS

The transdermal delivery system Fentanyl TDS wa [+]


Fentanyl TDS, Launched in Germany


Intro & Background | Presentation | Staff
Site Map | Legal Statement
Amarin Technologies S.A. © 2018   Design & Development: Mandarina